Vical (VICL) Stock Price Up 13.1% on Insider Buying Activity

Vical Incorporated (NASDAQ:VICL) traded up 13.1% during mid-day trading on Thursday following insider buying activity. The company traded as high as $1.21 and last traded at $1.21. 764,127 shares traded hands during mid-day trading, an increase of 251% from the average session volume of 217,698 shares. The stock had previously closed at $1.07.

Specifically, major shareholder Armistice Capital, Llc bought 145,297 shares of the firm’s stock in a transaction on Wednesday, June 13th. The stock was acquired at an average cost of $1.07 per share, with a total value of $155,467.79. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.58% of the stock is currently owned by insiders.

A number of brokerages have recently commented on VICL. Zacks Investment Research lowered shares of Vical from a “hold” rating to a “sell” rating in a research note on Thursday, May 10th. HC Wainwright set a $5.00 price target on shares of Vical and gave the stock a “buy” rating in a research note on Monday, May 7th. Finally, ValuEngine upgraded shares of Vical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

The company has a market capitalization of $26.30 million, a P/E ratio of -1.14 and a beta of 1.22.

Vical (NASDAQ:VICL) last announced its quarterly earnings results on Thursday, May 3rd. The biotechnology company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.12). Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. The company had revenue of $0.72 million during the quarter, compared to the consensus estimate of $2.10 million. research analysts anticipate that Vical Incorporated will post -1.08 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in VICL. Geode Capital Management LLC grew its position in Vical by 195.0% during the fourth quarter. Geode Capital Management LLC now owns 111,688 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 73,822 shares during the period. Millennium Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $256,000. Sabby Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $503,000. Ariel Investments LLC grew its position in Vical by 9.6% during the fourth quarter. Ariel Investments LLC now owns 637,913 shares of the biotechnology company’s stock valued at $1,167,000 after buying an additional 55,669 shares during the period. Finally, Stonepine Capital Management LLC bought a new stake in Vical during the fourth quarter valued at approximately $1,238,000. Institutional investors own 44.44% of the company’s stock.

About Vical

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy.

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit